Literature DB >> 3545529

Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat.

T E Emerson, M A Fournel, W J Leach, T B Redens.   

Abstract

Gram-negative septic shock remains a major clinical problem. One frequently encountered complication of sepsis is disseminated intravascular coagulation (DIC). The present study was to determine in an Escherichia coli endotoxemia awake rat model the efficacy of antithrombin-III (AT-III) prophylaxis and to explore the role of DIC in the pathogenesis of endotoxemia. We demonstrated that DIC occurs very early, before the appearance of detectable serious abnormalities in cardiovascular, metabolic, and biochemical variables indicative of organ damage or dysfunction; AT-III prophylaxis significantly ameliorates DIC, as evidenced by completely preventing the fall in plasma fibrinogen concentration and significantly limiting the increases in prothrombin time and activated partial thromboplastin time after 4 hours of endotoxemia; and AT-III prophylaxis dramatically increases permanent survival. Results of this study suggest that AT-III prophylaxis is very protective above a threshold dosage in an endotoxemic rat model and that protection is in part due to ameliorating DIC. Our data also suggest that DIC occurs very early during endotoxemia and may in part be responsible for the pathogenesis of endotoxemia in the rat. We conclude that AT-III prophylaxis may be efficacious in conditions of impending DIC, such as gram-negative septicemia/endotoxemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3545529

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  7 in total

Review 1.  Recombinant natural anticoagulants: a review.

Authors:  P L Harper; J M Hermans; R W Carrell
Journal:  J R Soc Med       Date:  1992-07       Impact factor: 5.344

2.  Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

3.  Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis.

Authors:  H Yamaguchi; H Weidenbach; H Lührs; M M Lerch; G Dickneite; G Adler
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

4.  Protection against endotoxin-induced foetal resorption in mice by desferrioxamine and ebselen.

Authors:  J D Gower; R J Baldock; A M O'Sullivan; C J Doré; C R Coid; C J Green
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

Review 5.  Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.

Authors:  Toshiaki Iba; Daizoh Saitoh
Journal:  J Intensive Care       Date:  2014-12-31

Review 6.  Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis.

Authors:  Christian J Wiedermann
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

7.  TYK2 licenses non-canonical inflammasome activation during endotoxemia.

Authors:  Andrea Poelzl; Caroline Lassnig; Simone Tangermann; Dominika Hromadová; Ursula Reichart; Riem Gawish; Kristina Mueller; Richard Moriggl; Andreas Linkermann; Martin Glösmann; Lukas Kenner; Mathias Mueller; Birgit Strobl
Journal:  Cell Death Differ       Date:  2020-09-14       Impact factor: 12.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.